

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

CHANGE OF AUTHORIZED REPRESENTATIVE

The board of directors (the “**Board**”) of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) announces that MinterEllison LLP has resigned as the Company’s authorized representative registered under the Hong Kong Companies Ordinance (Chapter 622 of the Laws of Hong Kong) with effect from 11 January 2024.

The Board also announces that Haiwen & Partners LLP has been appointed as the Company’s authorized representative registered under the Hong Kong Companies Ordinance (Chapter 622 of the Laws of Hong Kong) with effect from 11 January 2024.

Taking this opportunity, the Board would like to express its gratitude to MinterEllison LLP for its services rendered to the Company.

By Order of the Board

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 11 January 2024

As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Mr. Yang Jun, Ms. Cheng Ning, Ms. Liu Juyan, Mr. Zhang Chunbo, Mr. Wu Changhai, and Mr. Li Hong, as executive directors, and Mr. Chen Yajin, Mr. Huang Min, Mr. Wong Lung Tak Patrick and Ms. Sun Baoqing as independent non-executive directors.